New guidelines for occupational exposure to blood-borne viruses

Francisco Alvarado-Ramy, MD
Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA

Elise M. Beltrami, MD
Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA

Address: Francisco Alvarado-Ramy, MD, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Mailstop D-18, 1600 Clifton Road, Atlanta, GA 30333

This paper discusses treatments that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Francisco Alvarado-Ramy, MD
Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA

Elise M. Beltrami, MD
Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA

Address: Francisco Alvarado-Ramy, MD, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Mailstop D-18, 1600 Clifton Road, Atlanta, GA 30333

This paper discusses treatments that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Francisco Alvarado-Ramy, MD
Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA

Elise M. Beltrami, MD
Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA

Address: Francisco Alvarado-Ramy, MD, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Mailstop D-18, 1600 Clifton Road, Atlanta, GA 30333

This paper discusses treatments that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.